2023
Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis
Park D, An S, Arif A, Sana M, Vij A. Factor Xa inhibitors versus vitamin K antagonist in morbidly obese patients with venous thromboembolism: a systematic review and meta-analysis. BMC Cardiovascular Disorders 2023, 23: 100. PMID: 36814196, PMCID: PMC9945392, DOI: 10.1186/s12872-023-03067-4.Peer-Reviewed Original ResearchConceptsClinically relevant non-major bleedingNon-vitamin K antagonist oral anticoagulantsVitamin K antagonistsMorbidly obese patientsRecurrent venous thromboembolismObese patientsVenous thromboembolismFactor Xa inhibitorsK antagonistsXa inhibitorsTreating morbidly obese patientsVitamin K antagonist groupNon-major bleedingMeta-analysisTreat venous thromboembolismMeta-analysis of studiesHigh-risk populationAssociated with lower oddsRandomized controlled trialsOral anticoagulantsGoogle Scholar databasesMorbid obesityNo significant differenceLandmark trialsAtrial fibrillation
2022
Factor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis
Park D, An S, Arif A, Vij A. Factor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine 2022, 40: 82-83. DOI: 10.1016/j.carrev.2022.06.184.Peer-Reviewed Original ResearchCRT-500.16 Factor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis
Park D, An S, Arif A, Vij A. CRT-500.16 Factor Xa Inhibitors Versus Vitamin K Antagonist in Morbidly Obese Patients With Venous Thromboembolism: A Systematic Review and Meta-Analysis. JACC Cardiovascular Interventions 2022, 15: s49. DOI: 10.1016/j.jcin.2022.01.203.Peer-Reviewed Original Research